Halozyme Delivers Record FY2025 As 2026 Sets Up A Major Profitability Surge

Halozyme Therapeutics ( HALO ) is somewhat of a high-quality growth story. The future upside is being built on a scalable, royalty-driven platform that is now entering a pretty powerful earnings inflection point. FY25 earnings have just beenI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation ga ...